1637752-28-3

Usage

Uses

Used in Medicinal Chemistry:
Spiro[cyclopropane-1,3'-pyrrolo[2,3-c]pyridin]-2'(1'H)-one is used as a compound with potential applications in medicinal chemistry due to its unique molecular structure and the presence of heterocyclic systems, which are often found in pharmaceuticals.
Used in Materials Science:
In the field of materials science, spiro[cyclopropane-1,3'-pyrrolo[2,3-c]pyridin]-2'(1'H)-one is utilized for its rigid and unusual structure, which may contribute to the development of new materials with specific properties.

Upstream product

• 13091-23-1 4-chloro-3-nitropyridine 
• 784173-88-2 4-(methoxycarbomethyl)-3-nitropyridine 
• 1309801-77-1 methyl 2-(3-nitro-4-pyridyl)prop-2-enoate 
• 3430-22-6 3-Bromo-4-methylpyridin 
• 51054-99-0 ethyl 2-(3-bromopyridin-4-yl)acetate 
• 65645-52-5 ethyl 2-(3-nitro-pyridin-4-yl)acetate 
• 2530-26-9 3-nitropyridine 
• 106-93-4 ethylene dibromide 

Relevant academic research and scientific papers

FLUOROALKYL-OXADIAZOLES AND USES THEREOF

Provided herein are compounds identified as inhibitors of HDAC6 activity that can be used to treat various diseases and disorders.

Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion

RV521 is an orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion that was identified after a lead optimization process based upon hits that originated from a physical property directed hit profiling exercise at Reviral. This exercise encompassed collaborations with a number of contract organizations with collaborative medicinal chemistry and virology during the optimization phase in addition to those utilized as the compound proceeded through preclinical and clinical evaluation. RV521 exhibited a mean IC50 of 1.2 nM against a panel of RSV A and B laboratory strains and clinical isolates with antiviral efficacy in the Balb/C mouse model of RSV infection. Oral bioavailability in preclinical species ranged from 42 to >100% with evidence of highly efficient penetration into lung tissue. In healthy adult human volunteers experimentally infected with RSV, a potent antiviral effect was observed with a significant reduction in viral load and symptoms compared to placebo.

SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV)

Benzimidazoles of formula (I): wherein: one of X and Y is an N atom or a substituted C atom, and the other is CH; L is a single bond, C1-3 alkylene, C2-3 alkenylene or C2-3 alkynylene; R1 is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 3- to 10-membered cycloalkyl, 5- to 10-membered heterocyclyl or 5- to 12- membered heteroaryl, each of which is unsubstituted or substituted; Z is halo, C1-6 haloalkyl, nitro, -CN, -N(R2)2, -OR2, -SR2, -S(=0)R2, or -S(=0)2R2; each R2 is independently hydrogen, C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, wherein said alkyl, alkenyl and alkynyl groups are unsubstituted or substituted; and m is 0 or 1; and the pharmaceutically acceptable salt thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.

NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION

The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, W and X are as described herein, compositions including the compounds and methods of using the compounds.

NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION

The invention provides novel compounds having the general formula:(I) wherein R1, R2, R3, R4, W and X are as described herein, compositions including the compounds and methods of using the compounds.